Effects of naproxen on uterine contractility in vivo.
An in vivo technique for monitoring uterine contractility has been developed and used to assess the effects of naproxen on both spontaneous motility and that due to exogenous PGF2 alpha in the hamster and the rat. Naproxen has been shown to suppress uterine motility in both situations, in both species, whether administered by parenteral or oral routes. The hamster was shown to be approximately 10 X less sensitive to naproxen than is the rat (625 mg/kg vs 62.5 mg/kg) but conversely was 100 X more sensitive than rat to uterine contractive effects of PGF 2 alpha (10 ng vs 1000 ng).
D000818:Animals; D006224:Cricetinae; D004347:Drug Interactions; D005260:Female; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D009288:Naproxen / Q000494:pharmacology*; D011247:Pregnancy; D011453:Prostaglandins / Q000494:pharmacology; D011460:Prostaglandins F / Q000494:pharmacology; D051381:Rats; D013045:Species Specificity; D013116:Spinal Cord / Q000502:physiology; D013997:Time Factors; D014590:Uterine Contraction / Q000187:drug effects*
D011453:Prostaglandins; D011460:Prostaglandins F; D009288:Naproxen; D007545:Isoproterenol